美国将投资于艾滋病毒药物Lenacapavir,到2028年将目标对准较贫穷国家200万剂量。 U.S. to invest in HIV drug lenacapavir, targeting 2 million doses to poorer nations by 2028.

美国政府计划投资莱纳卡帕维尔(lenacapavir), 这是一种预防艾滋病毒的新药, 目的是到2028年向中低收入国家的人们提供高达200万剂量的药物。 The U.S. government plans to invest in lenacapavir, a new HIV prevention drug, aiming to provide up to 2 million doses by 2028 to people in low- and middle-income countries. 该药物由Gilead Science公司研制,每年两次注射一次,提供几乎完全的艾滋病毒预防保护,并可以防止母婴传播。 The drug, developed by Gilead Sciences, offers almost complete protection against HIV with twice-yearly injections and can prevent mother-to-child transmission. 这项财政承诺是与全球基金建立伙伴关系的,其目的是在病毒最流行的国家中防治这种病毒。 The financial commitment, a partnership with the Global Fund, aims to combat the virus in countries where it's most prevalent.